WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Baruch D. Kuppermann, MD, PhD, discusses positive data from real-world studies assessing intravitreal implants for diabetic macular edema.
According to Kuppermann, Steinert Endowed Professor and chair of the department of ophthalmology and visual sciences at the University of California, Irvine, patients in the ERLYDEX study with suboptimal responses to anti-VEGF therapy who were switched to Ozurdex (dexamethasone intravitreal implant, AbbVie) “showed benefit compared with those that were maintained on anti-VEGF both in terms of